Doug has over 20 years of experience working in the life sciences industry, with more than a decade in strategy consulting. He collaborates with a range of organizations, from large biopharmaceutical companies to clinical-stage biotechnology firms as well as private equity and medical device clients.
Our most successful engagements are those where we work with our clients as thought partners, we impact the organization’s thinking and decisions, and we have some fun together doing it.”
Doug has supported life sciences organizations on projects spanning numerous therapeutic areas, including cardiology, central nervous system, dermatology, hematology, immunology, inflammation, metabolics, oncology, rare disease, rheumatology and women’s health.
Throughout his career, Doug has led clients through:
- Corporate and franchise strategy development to articulate where organizations should compete and why.
- Commercial and market access strategy creation to optimize the performance of existing assets, from cross-functional launch planning through life cycle management.
- Technology platform and portfolio strategy development to strengthen businesses organically, including investment prioritization across a full portfolio of assets.
- Formulating business development strategies to strengthen their portfolios from external sources, including needs identification, search and evaluation, due diligence and valuation.
Prior to joining Huron, Doug worked for The Frankel Group LLC for eight years, where he led an array of strategy projects for life sciences clients. Doug has also served as a case team leader for Bain & Company, and the head of engineering for the surgical division of medical device firm Getinge.
Doug holds a Master of Business Administration, with honors, from Columbia Business School and graduated summa cum laude with a Bachelor of Science in mechanical engineering from Duke University.